TY - JOUR
T1 - A Score to Assess Mortality After Percutaneous Mitral Valve Repair
AU - Raposeiras-Roubin, Sergio
AU - Adamo, Marianna
AU - Freixa, Xavier
AU - Arzamendi, Dabit
AU - Benito-González, Tomas
AU - Montefusco, Antonio
AU - Pascual, Isaac
AU - Nombela-Franco, Luis
AU - Rodes-Cabau, Josep
AU - Shuvy, Mony
AU - Portolés-Hernández, Antonio
AU - Godino, Cosmo
AU - Caneiro-Queija, Berenice
AU - Lupi, Laura
AU - Regueiro, Ander
AU - Li, Chin Hion
AU - Fernández-Vázquez, Felipe
AU - Frea, Simone
AU - Avanzas, Pablo
AU - Tirado-Conte, Gabriela
AU - Paradis, Jean Michel
AU - Peretz, Alona
AU - Moñivas, Vanessa
AU - Baz, Jose A.
AU - Galasso, Michele
AU - Branca, Luca
AU - Sanchís, Laura
AU - Asmarats, Lluís
AU - Garrote-Coloma, Carmen
AU - Angelini, Filippo
AU - León, Victor
AU - Pozo, Eduardo
AU - Alperi, Alberto
AU - Beeri, Ronen
AU - Cani, Dario
AU - Sabaté, Manel
AU - Fernández-Peregrina, Estefanía
AU - Gualis, Javier
AU - Bocchino, Pier Paolo
AU - Curello, Salvatore
AU - Abu-Assi, Emad
AU - Íñiguez-Romo, Andrés
AU - Bedogni, Francesco
AU - Rubbio, Antonio Popolo
AU - Testa, Luca
AU - Grasso, Carmelo
AU - Estévez-Loureiro, Rodrigo
N1 - Publisher Copyright:
© 2022 American College of Cardiology Foundation
PY - 2022/2/15
Y1 - 2022/2/15
N2 - Background: Risk stratification for transcatheter edge-to-edge mitral valve repair (TEER) is paramount in the decision-making process for treating severe mitral regurgitation (MR). Objectives: This study sought to create and validate a user-friendly score (MitraScore) to predict the risk of mortality in patients undergoing TEER. Methods: The derivation cohort was based on a multicentric international registry that included 1,119 patients referred for TEER between 2012 and 2020. Score discrimination was assessed using Harrell's c-statistic, and the calibration was evaluated with the Gronnesby and Borgan goodness-of-fit test. An external validation was carried out in 725 patients from the GIOTTO registry. Results: After multivariate analysis, we identified 8 independent predictors of mortality during the follow-up (2.1 ± 1.8 years): age ≥75 years, anemia, glomerular filtrate rate <60 mL/min/1.73 m2, left ventricular ejection fraction <40%, peripheral artery disease, chronic obstructive pulmonary disease, high diuretic dose, and no therapy with renin-angiotensin system inhibitors. The MitraScore was derived by assigning 1 point to each independent predictor. The c-statistic was 0.70. Per each point of the MitraScore, the relative risk of mortality increased by 55% (HR: 1.55; 95% CI: 1.44-1.67; P < 0.001). The discrimination and calibration for mortality prediction was better than those of EuroSCORE II (c-statistic 0.61) or Society of Thoracic Surgeons score (c-statistic 0.57). The MitraScore maintained adequate performance in the validation cohort (c-statistic 0.66). The score was also predictive for heart failure rehospitalization and was correlated with the probability of clinical improvement. Conclusions: The MitraScore is a simple prediction algorithm for the prediction of follow-up mortality in patients treated with TEER.
AB - Background: Risk stratification for transcatheter edge-to-edge mitral valve repair (TEER) is paramount in the decision-making process for treating severe mitral regurgitation (MR). Objectives: This study sought to create and validate a user-friendly score (MitraScore) to predict the risk of mortality in patients undergoing TEER. Methods: The derivation cohort was based on a multicentric international registry that included 1,119 patients referred for TEER between 2012 and 2020. Score discrimination was assessed using Harrell's c-statistic, and the calibration was evaluated with the Gronnesby and Borgan goodness-of-fit test. An external validation was carried out in 725 patients from the GIOTTO registry. Results: After multivariate analysis, we identified 8 independent predictors of mortality during the follow-up (2.1 ± 1.8 years): age ≥75 years, anemia, glomerular filtrate rate <60 mL/min/1.73 m2, left ventricular ejection fraction <40%, peripheral artery disease, chronic obstructive pulmonary disease, high diuretic dose, and no therapy with renin-angiotensin system inhibitors. The MitraScore was derived by assigning 1 point to each independent predictor. The c-statistic was 0.70. Per each point of the MitraScore, the relative risk of mortality increased by 55% (HR: 1.55; 95% CI: 1.44-1.67; P < 0.001). The discrimination and calibration for mortality prediction was better than those of EuroSCORE II (c-statistic 0.61) or Society of Thoracic Surgeons score (c-statistic 0.57). The MitraScore maintained adequate performance in the validation cohort (c-statistic 0.66). The score was also predictive for heart failure rehospitalization and was correlated with the probability of clinical improvement. Conclusions: The MitraScore is a simple prediction algorithm for the prediction of follow-up mortality in patients treated with TEER.
KW - mortality
KW - score
KW - transcatheter edge-to-edge mitral valve repair
KW - Follow-Up Studies
KW - Humans
KW - Risk Factors
KW - Male
KW - Stroke Volume/physiology
KW - Treatment Outcome
KW - Mitral Valve/surgery
KW - Heart Valve Prosthesis Implantation/adverse effects
KW - Mitral Valve Insufficiency/mortality
KW - Time Factors
KW - Cardiac Catheterization/adverse effects
KW - Italy/epidemiology
KW - Postoperative Complications/mortality
KW - Female
KW - Registries
KW - Aged
KW - Retrospective Studies
UR - http://www.scopus.com/inward/record.url?scp=85123680846&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2021.11.041
DO - 10.1016/j.jacc.2021.11.041
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35144748
AN - SCOPUS:85123680846
SN - 0735-1097
VL - 79
SP - 562
EP - 573
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 6
ER -